✦ LIBER ✦

Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a cancer and leukemia group B study

✍ Scribed by Jeffrey B. Hargis; James R. Anderson; Kathleen J. Propert; Mark R. Green; David A. Echo

Book ID: 104887165
Publisher: Springer
Year: 1992
Tongue: English
Weight: 703 KB
Volume: 30
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00686298

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphisms and the efficacy a

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients

✍ Khrunin, A V; Moisseev, A; Gorbunova, V; Limborska, S 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 403 KB

Etoposide in combination as first-line c

Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A cancer and leukemia group B study

✍ Jeffrey J. Kirshner; James R. Anderson; Barbara Parker; Maurice Barcos; M. Rober 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 468 KB 👁 1 views

Background. In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Thirty-six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophos

7166 Predicting and preventing thrombo-e

7166 Predicting and preventing thrombo-embolic events in patients with germ-cell tumors receiving cisplatin-based chemotherapy

✍ Oberic, L.; de la Motte Rouge, T.; Massard, C.; Gross-Goupil, M.; Loriot, Y.; Es 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Prognostic factors for survival in patie

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

✍ Polee, M B; Hop, W C J; Kok, T C; Eskens, F A L M; van der Burg, M E L; Splinter 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Supplementation with antioxidant micronu

Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study

✍ N.I Weijl; T.J Elsendoorn; E.G.W.M Lentjes; G.D Hopman; A Wipkink-Bakker; A.H Zw 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Platinum-based combination chemotherapy

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B

✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received